Expertise in
1
conditions

Quanli L. Gao

No. 127 Dongming Road, 
Zhengzhou, CN 
Expertise in
1
conditions
No. 127 Dongming Road, 
Zhengzhou, CN 

Overview

Quanli Gao practices practicing medicine in Zhengzhou, China.

Gao is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Melanoma, Gastroesophageal Junction Cancer, Renal Cell Carcinoma (RCC), and Classical Hodgkin Lymphoma.

They are actively involved in clinical research, co-authoring 100 peer reviewed articles and participating in 2 clinical trials.

Locations

No. 127 Dongming Road, Zhengzhou, 450008, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase I/II Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TJ011133 in Combination With Toripalimab in Subjects With Advanced Solid Tumors
A Phase I/II Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TJ011133 in Combination With Toripalimab in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: April 15, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase Ⅱ Study
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase Ⅱ Study
Enrollment Status: Terminated
Publish Date: May 12, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 1 Less Clinical Trial

100 Total Publications

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.
Journal: JAMA oncology
Published: January 02, 2026

Frequently Asked Questions about Quanli L. Gao

Is Quanli L. Gao a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Quanli L. Gao is classified as an Advanced expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Quanli L. Gao participate in research or clinical trials?

Yes. Quanli L. Gao has published 100 articles and abstracts on conditions like Melanoma. You can view a list of Quanli L. Gao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Gao's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile